Venus Medtech (Hangzhou) Inc
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company's offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to tre… Read more
Market Cap & Net Worth: Venus Medtech (Hangzhou) Inc (VMTHF)
Venus Medtech (Hangzhou) Inc (PINK:VMTHF) has a market capitalization of $173.67 Million ($173.67 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #17684 globally and #6677 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Venus Medtech (Hangzhou) Inc's stock price $0.39 by its total outstanding shares 441010235 (441.01 Million).
Venus Medtech (Hangzhou) Inc Market Cap History: 2021 to 2025
Venus Medtech (Hangzhou) Inc's market capitalization history from 2021 to 2025. Data shows change from $2.12 Billion to $173.67 Million (-54.51% CAGR).
Venus Medtech (Hangzhou) Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Venus Medtech (Hangzhou) Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Venus Medtech (Hangzhou) Inc's market cap is 0.01 times its annual revenue
0.67x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.12 Billion | $415.86 Million | -$373.64 Million | 5.09x | N/A |
| 2022 | $732.08 Million | $406.46 Million | -$1.06 Billion | 1.80x | N/A |
| 2023 | $283.39 Million | $491.37 Million | -$703.75 Million | 0.58x | N/A |
| 2024 | $4.76 Million | $470.83 Million | -$714.31 Million | 0.01x | N/A |
Competitor Companies of VMTHF by Market Capitalization
Companies near Venus Medtech (Hangzhou) Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Venus Medtech (Hangzhou) Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Venus Medtech (Hangzhou) Inc Historical Marketcap From 2021 to 2025
Between 2021 and today, Venus Medtech (Hangzhou) Inc's market cap moved from $2.12 Billion to $ 173.67 Million, with a yearly change of -54.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $173.67 Million | +3546.30% |
| 2024 | $4.76 Million | -98.32% |
| 2023 | $283.39 Million | -61.29% |
| 2022 | $732.08 Million | -65.42% |
| 2021 | $2.12 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Venus Medtech (Hangzhou) Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $173.67 Million USD |
| MoneyControl | $173.67 Million USD |
| MarketWatch | $173.67 Million USD |
| marketcap.company | $173.67 Million USD |
| Reuters | $173.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.